Supernus Pharmaceuticals, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.0 months). See all sponsors →
Open Supernus Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SPN-812 NCT02736656 |
P3 | Active, not recruiting | Attention-Deficit/Hyperactivity Disorder | 1400 | 2026-12 (+92 mo) |
| FIAS NCT03474770 |
P1/2 | Active, not recruiting | Focal Impaired Awareness Seizures | 16 | 2026-12-30 |
| SPN-821 2400 mg NCT07226661 |
P2 | Recruiting | Major Depressive Disorder (MDD) | 230 | 2026-12-31 |
| SPN-817 NCT06798896 |
P2 | Recruiting | Focal Onset Seizures | 216 | 2027-08 (+10 mo) |
| SPN-817 NCT05518578 |
P2 | Recruiting | Epilepsy; Seizures, Epileptic | 60 | 2027-12-31 (+39 mo) |
| SPN-817 NCT07141329 |
P2 | Enrolling by invitation | Focal Onset Seizures | 100 | 2027-12-31 |